Halucenex teams up with Sixth Wave; Californian legislation another leg-up for Creso Pharma


  • Creso Pharma’s target acquisition company Halucenex has signed a non-binding LOI with Sixth Wave Innovations Inc.
  • Halucenex and Sixth Wave will develop beads and columns to assist the production of psilocybin isolate and other wellness components of psilocybe mushroom strains.
  • The Company welcomes the Californian legalisation of psychedelics, which could benefit Creso Pharma and Halucenex in the US.

Creso Pharma Limited (ASX:CPH, FRA:1X8) updated the market on Monday that its acquisition target, Halucenex Life Sciences Inc, has signed a Letter of Intent (LOI) with Sixth Wave Inc, which is a prominent nanotechnology firm. Creso Pharma also provided an update on the recent legislative change in North America about the possession and use of psychedelic compounds, which could benefit Creso Pharma and Halucenex in the future.

Halucenex signs LOI with a leading nanotechnology company

Halucenex and Sixth Wave have signed a Letter of Intent to work on developing a Definitive Agreement by 31 May 2021. Both the parties are set to work on creating beads and columns to assist the production of psilocybin isolate from the distillation of the product.

This will allow Halucenex to manufacture a natural pure psilocybin product for further R&D. It will also offer accurate dosing of psilocybin to treat mental disorders.

ALSO READ: Creso Pharma (ASX:CPH) bolsters its presence in Africa with Cannabis Queen agreement


Halucenex to conduct research into the health and wellness

The two parties will develop columns and beads psilocybe mushroom strains’ other wellness components, including norbeocystin  and baeocystin.  Furthermore, Halucenex can carry out research for the health benefits of these molecules, with no hallucinogenic effects of psilocybin present.

Halucenex anticipates that work done in collaboration with Sixth Wave will also complement the Advanced Extraction agreement and the Growing Together Research Inc (GTR). Halucenex and GTR can identify important psilocybe genetic markers, facilitating the extraction as well as separation processes to offer consistency and purity of the compounds.

ALSO READ: Creso Pharma welcomes milestone developments by acquisition target Halucenex

Sixth Wave in a nutshell

  • Vancouver, Canada-based Sixth Wave (CSE:SIXW) is focused on developing nanotechnology that uses MIPs (Molecularly Imprinted Polymers).
  • The MIPs are used for imprinting, capturing, and releasing substances at a molecular level.
  • The systems of Sixth Wave are empowered by MIPs and result in a more efficient extraction system churning out purer end products or detection findings.
  • Sixth Wave has established MIP supported completely scalable systems, which are anticipated to replace antiquated and traditional extraction processes delivering considerable advancements, like cost savings and better yields.
  • The products of Sixth Wave are currently being commercialised across various sectors, including cannabis productions, mining, and health security with swift virus detection.

Halucenex to use patent-pending technology of Sixth Wave

Interestingly, Sixth Wave has collaborated and undertaken R&D initiatives with some of the largest entities in the chemical, resources, security, defence and medical sectors.  The systems are patented or patent-pending in more than forty countries.  

The application of Sixth Wave’s patent-pending nanotechnology to purify the botanical psychedelics will streamline the processes and provide a sustainable method for utilising natural plant extracts contrasting the use of synthetic molecules. The use of synthetic molecules may not offer similar access and flexibility to use the plant-associated compounds for attaining the best clinical advantages.

Halucenex anticipates using the patent-pending technology, alongside agreements with other key partners, to expand its R&D initiatives.

ALSO READ: Creso beefs up Canadian business as Mernova secures new POs, product launches

California to decriminalise psychedelics

In another exciting development, the Company has welcomed the latest motion to move towards the legalisation of psychedelic substances in California.  The Senate Public Safety Committee approved Senate Bill 519 on 13 April 2021.

The Bill would make a comprehensive range of psychedelic substances legal to use and possess for adults over the age of 21, as well as remove any previous criminal offences for use and possession.

The Bill has been launched to progress a more health-focused methodology to the use of psychedelic compounds and to address the current mental health crisis in the US.

Moreover, it also marks the ongoing push towards acceptance of psychedelic compounds as an alternate treatment route.

Creso Pharma will work with its Director of US Business Development, Mr John Griese, to progress opportunities in California if this bill turns into law.

DO READ: Creso Pharma aims to make inroads in US cannabis space with latest appointment

Management Commentary

Adam Blumenthal, Non-executive Chairman of Creso, stated that the recent LOI with Sixth Wave is a significant development for Halucenex and can offer substantial upside to near term initiatives in the clinical trial as well as cultivation activities.

Mr Blumenthal further added-

Adding to this, Bill Fleming, Founder and CEO of Halucenex commented-

Dr Jon Glucklman, President and CEO of Sixth Wave said:

On 20 April 2021, CPH shares were trading at AU$0.200, at AEST 01:18 PM.  

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK